LIPO Lipella Pharmaceuticals Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.31
P/S
2.66
EV/EBITDA
0.21
DCF Value
$-7.42
FCF Yield
-511078.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1954.7%
Operating Margin
-3115.2%
Net Margin
-3069.0%
ROE
-208.4%
ROA
-226.8%
ROIC
-308.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 null | $0.00 | $-1.3M | $— |
| Q2 null | $0.00 | $-1.3M | $— |
| Q1 null | $0.00 | $-1.3M | $— |
| Q4 null | $173.7K | $-1.4M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.